Ranbaxy
Ranbaxy
படிக்க எடுத்துக்கொள்ளும் நேரம்: 2 நிமிடங்கள்
Ranbaxy
Ranbaxy

The whistleblower, Dinesh Thakur, has been awarded $48.6 million in settlement after Ranbaxy agreed to pay $500 million (Rs2,737 crore) to settle the five-year-old case.

A former employee of Ranbaxy Laboratories got Rs266 crore after the US Department of Justice on Monday found the company guilty of violating that country’s Food and Drugs Act and making false claims to the Food and Drug Administration (FDA).

The whistleblower, Dinesh Thakur,  has been awarded $48.6 million in settlement after Ranbaxy agreed to pay $500 million (Rs2,737 crore) to settle the five-year-old case.

Thakur worked in the intellectual property cell of the pharmaceutical firm and was among a batch of seniors who quit the firm a couple of years ago.

This is the largest drug safety settlement with a generic drugmaker, according to the US Department of Justice.

Of the settlement, the US government will get about $231.8 million (Rs1,269 crore), while other states participating in the case will get $118.2 million (Rs647 crore).

Ranbaxy’s US unit pleaded guilty to felony charges relating to manufacture and distribution of adulterated drugs made at two facilities in India.

Ranbaxy will have to pay $150 million as criminal fine and forfeiture and $350 million to settle civil claims under False Claims Act and various state laws.

Ranbaxy US pleaded guilty to three felony counts of violating the Food, Drug and Cosmetic Act, and four felony counts of knowingly making false statements to the FDA.

The case dates to 2008, when the FDA banned dozens of Ranbaxy’s generic drugs from entering the US due to violations of its manufacturing and quality standards at two of Ranbaxy’s plants in India.

Ranbaxy had set aside a provision of $500 million in January last year after the Department of Justice filed a consent decree of permanent injunction on behalf of the FDA to cover any liability arising out of a separate investigation.